Fianlimab clinical trials
Fianlimab is named as an intervention in 14 current clinical trials in our USA, Spain, Canada, France, Turkey, Australia, Germany, Italy, Mexico, Israel, South Korea, Taiwan, Ireland, UK, Belgium, Poland, Austria, Czechia, Brazil, Netherlands and Japan registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Regeneron Pharmaceuticals (12). The most-studied condition is Melanoma.
How Fianlimab works
All drug targets →- Lymphocyte activation gene 3 protein inhibitor InhibitorTarget: LAG3 lymphocyte activating 3✓ In ChEMBL and the Guide to Pharmacology
- MelanomaPhase 3
- Non-small cell lung carcinomaPhase 2/3
- Basal cell carcinomaPhase 2
- Clear cell renal carcinomaPhase 2
- Colon carcinomaPhase 2
- Colorectal cancerPhase 2
- Cutaneous squamous cell carcinomaPhase 2
- Head and neck cancerPhase 2
- Head and neck squamous cell carcinomaPhase 2
- Hepatocellular carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4298085, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14532, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Fianlimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Fianlimab
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Fianlimab
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| Melanoma | 5 |
| Non-small Cell Lung Cancer | 2 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Primary Peritoneal Cancer | 1 |
| Resectable Non-small Cell Lung Cancer | 1 |
| Multiple Myeloma | 1 |
| Hepatocellular Carcinoma | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Pleural Mesotheliomas | 1 |
| Melanoma BRAF V600E/K Mutated | 1 |
| Melanoma and Brain Metastases | 1 |
| Advanced Malignancies | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 12 |
| Intergroupe Francophone de Cancerologie Thoracique | 1 |
| Grupo Español Multidisciplinar de Melanoma | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Fianlimab trials
How many clinical trials are testing Fianlimab?
14 current trials in our USA, Spain, Canada, France, Turkey, Australia, Germany, Italy, Mexico, Israel, South Korea, Taiwan, Ireland, UK, Belgium, Poland, Austria, Czechia, Brazil, Netherlands and Japan registers name Fianlimab (also registered as REGN3767) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Fianlimab trials recruiting patients?
Yes. 5 of the 14 trials are recruiting: 3 with sites in USA, 2 with sites in Spain, 2 with sites in Canada, 2 with sites in France, 1 with sites in Turkey, 1 with sites in Israel, 1 with sites in South Korea and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Fianlimab clinical trials?
Regeneron Pharmaceuticals (12), Intergroupe Francophone de Cancerologie Thoracique (1) and Grupo Español Multidisciplinar de Melanoma (1). The number in brackets is how many trials each organisation leads.
Are there Fianlimab clinical trials in Ireland?
Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fianlimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fianlimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fianlimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.